GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » EPS without NRI

Galapagos NV (Galapagos NV) EPS without NRI : $-0.17 (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV EPS without NRI?

Galapagos NV's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.65. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.17.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 58.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Galapagos NV's EPS without NRI or its related term are showing as below:

GLPGF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -214.7   Med: -7.6   Max: 71.1
Current: 58.8

During the past 13 years, Galapagos NV's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 71.10% per year. The lowest was -214.70% per year. And the median was -7.60% per year.

GLPGF's 3-Year EPS without NRI Growth Rate is ranked better than
94.06% of 1296 companies
in the Biotechnology industry
Industry Median: 4.8 vs GLPGF: 58.80

Galapagos NV's EPS (Diluted) for the three months ended in Dec. 2023 was $2.61. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.48.

Galapagos NV's EPS (Basic) for the three months ended in Dec. 2023 was $2.61. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $3.48.


Galapagos NV EPS without NRI Historical Data

The historical data trend for Galapagos NV's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV EPS without NRI Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.72 -4.27 -2.87 -1.78 -0.27

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.53 -0.04 -0.02 -0.65

Competitive Comparison of Galapagos NV's EPS without NRI

For the Biotechnology subindustry, Galapagos NV's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Galapagos NV's PE Ratio without NRI falls into.



Galapagos NV EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (OTCPK:GLPGF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Galapagos NV EPS without NRI Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.